[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Clinical and biological significance of RAS mutations in multiple myeloma

Leukemia volume 22, pages 2280–2284 (2008)Cite this article

Access through your institution
Buy or subscribe

Primary genetic abnormalities in myeloma (MM) such as trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 associated with hyperdiploid MM and translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 and three main recurrent partners: MMSET/FGFR3, CCND1 and c-MAF are already present in the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) stage.1 Some patients with these genetic abnormalities may remain as MGUS for many years without transforming to MM, suggesting that they are involved in clonal initiation but do not mediate malignant transformation.

One of the recurrent differences between MGUS and MM is the presence of RAS mutations in the latter. RAS mutations may, therefore, play an important role in malignant transformation of clonal plasma cells and myeloma pathogenesis. However, the clinical and biological significance of RAS mutation in MM has not been clearly established as most of the previous studies have involved small numbers of heterogeneously treated patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM . Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571–596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    Article  CAS  PubMed  Google Scholar 

  3. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999; 35: 83–89.

    Article  CAS  PubMed  Google Scholar 

  4. Oken MM, Leong T, Lenhard Jr RE, Greipp PR, Kay NE, Van Ness B et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999; 86: 957–968.

    Article  CAS  PubMed  Google Scholar 

  5. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM . Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323.

    Article  CAS  PubMed  Google Scholar 

  6. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212–224.

    Article  CAS  PubMed  Google Scholar 

  7. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD . Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001; 98: 1555–1560.

    Article  CAS  PubMed  Google Scholar 

  8. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582–584.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA

    W J Chng, S Van Wier & R Fonseca

  2. Division of Haemtology, Mayo Clinic, Rochester, MN, USA

    N Gonzalez-Paz, T Price-Troska, S V Rajkumar, R A Kyle, K J Henderson & P Greipp

  3. Eastern Cooperative Oncology Group Statistical Center, Dana Faber Cancer Institute, Boston, MA, USA

    S Jacobus

  4. Department of Oncology, North Memorial Cancer Center, Minneapolis, MN, USA

    M M Oken

  5. Department of genetics, cell biology and development, University of Minnesota, Mineapolis, MN, USA

    B Van Ness

  6. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

    W J Chng

  7. Department of Haematology-Oncology, National University Hospital, Singapore

    W J Chng

Authors
  1. W J Chng
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. N Gonzalez-Paz
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. T Price-Troska
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. S Jacobus
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. S V Rajkumar
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. M M Oken
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. R A Kyle
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. K J Henderson
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. S Van Wier
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. P Greipp
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. B Van Ness
    View author publications

    You can also search for this author inPubMed Google Scholar

  12. R Fonseca
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to R Fonseca.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chng, W., Gonzalez-Paz, N., Price-Troska, T. et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 22, 2280–2284 (2008). https://doi.org/10.1038/leu.2008.142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.142

Search

Advanced search

Quick links